ImmuneOnco：Clinical Research Application for IMM27M was accepted by the National Medical Products Administration (NMPA)
On September 1, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that clinical research application for newly developed IMM27M, an ADCC-enhanced CTLA-4 antibody, has been officially accepted by National Medical Products Administration (NMPA).
IMM27M is an IgG1 antibody targeting CTLA-4 that has been genetically engineered to enhance the activity of ADCC. IMM27M has better efficacy than Ipilimumab at the same dose in animals, and it can eliminate tumors completely at a lower dose 0.3mg/kg.
Dr. Tian Wenzhi, founder of ImmuneOnco, said: "I am very pleased that the clinical research application of our new generation CTLA-4 antibody project has been accepted by NMPA. Repeatable in vivo studies have proved that IMM27M owns strong anti-tumor activity. Most importantly, it can be combined with a variety of drugs in the company's pipeline for clinical research. We believe that IMM27M will have great clinical developmental value. " Dr. Tian is full of confidence in the clinical development of IMM27M.
IMM27M is a new generation of CTLA-4 antibody independently developed by ImmuneOnco. It's with enhanced ADCC activity through genetic engineering technology and can completely eliminate Treg cells in the tumor microenvironment. IMM27M has strong efficacy as a single agent, or can combine with a variety of drugs in the company's product pipeline, such as IMM01 (CD47), IMM2510 (VEGF/PD-L1), IMM2902 (CD47/HER2) or IMM2520 (CD47/PD-L1).
Founded in June 2015 at Zhangjiang Hi-Tech Park of China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bi-specific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’ own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can return gradually to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.